Ceribell (CBLL) Capital Expenditures (2023 - 2026)

Ceribell (CBLL) posted Capital Expenditures of -$6000.0 for Q1 2026, up 96.53% on a QoQ basis from -$173000.0 in Q4 2025.

Ceribell (CBLL) Capital Expenditures (2023 - 2026) Analysis & Trends

Ceribell's Capital Expenditures history runs 4 years deep, the most recent figure standing at -$6000.0 for Q1 2026.

Quarterly Capital Expenditures changed N/A year-over-year to -$6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $409000.0 (up 268.47% YoY) and the FY2025 annual result came in at $415000.0, up 538.46% from the prior year.
Capital Expenditures was -$6000.0 for Q1 2026 at Ceribell, up from -$173000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $881000.0 in Q3 2024 and bottomed at -$918000.0 in Q4 2024.
A 4-year average of $105666.7 and a median of $148000.0 in 2024 frame the typical range for Capital Expenditures.
Annual changes were most pronounced in 2024 — Capital Expenditures plunged 292.45% — and 2025, when it jumped 81.15%.
Ceribell's Capital Expenditures stood at $477000.0 in 2023, then plunged by 292.45% to -$918000.0 in 2024, then soared by 81.15% to -$173000.0 in 2025, then jumped by 96.53% to -$6000.0 in 2026.
Business Quant data shows CBLL's Capital Expenditures at -$6000.0 in Q1 2026, -$173000.0 in Q4 2025, and $362000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	399.00 Mn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	166.00 Mn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	488.00 Mn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	177.00 Mn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	64.90 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	76.60 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	-85.46 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	178.00 Mn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Ceribell	613.16 Mn	471.97 Mn	23.12 Mn	-6,000.00

Download Data